Stock Taper
SCREENER COMPARE ANY 2 STOCKS
JANX
JANUX THERAPEUTICS, INC.
NASDAQ
$18.03
▼ DOWN 3.99% (-0.75)

KEY STATISTICS

Market Cap$1.10 B
52w High$35.34
52w Low$12.12
Dividend Yield—
Frequency—
P/E-10.99
Volume637.81K
Shares Out.60.98M

COMPANY

LEADERSHIP

David Alan Campbell
CHIEF EXECUTIVE
David Alan Campbell

COMPENSATION 2026

Salary$625,000
Stock Awards$0
Incentive Plan Pay$412,500
All Other Comp.$0
Total$4,193,269

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 11, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
113

PRICE TARGET

Target High$55.00
Target Low$14.00
Target Median$24.50
Target Consensus$28.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$8.03M
NOV
5
THU

PRICE

$18.03 ▼ DOWN 3.99% (−$0.75)
$18.00$18.25$18.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM18.03

About Janux Therapeutics, Inc.

https://www.januxrx.com ↗

Janux Therapeutics, Inc. develops tumor-activated T cell engager and immunomodulator therapies targeting various cancer antigens, with lead candidates in preclinical stages, to enhance anti-tumor immune responses.

INDUSTRY

Biotechnology

A PRODUCT JANUX THERAPEUTICS, INC. IS KNOWN FOR

JANX011
JANX011

JANX011, a CD19-targeted bispecific therapeutic developed via Janux's ARM platform, is in Phase 1 for autoimmune diseases, marking the company's first clinical candidate beyond oncology, with the first patient dosed in February 2026.

COMPETITORS

COMPETITOR
AGEN COMPARE
AMGN COMPARE
CGEM COMPARE
CTMX COMPARE
IMTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
123
LISTED HERE
21
RANKED BY POSITION SIZE
XBI
0.32% · 2.1M
VTI
0.00% · 1.3M
IWM
0.03% · 1.1M
SCHA
0.02% · 234.2K
FSCC
0.92% · 183.3K
DFAS
0.01% · 123.0K
LABU
0.22% · 74.8K
AVSC
0.03% · 56.1K
CANC
0.46% · 54.0K
XRSU.L
0.03% · 39.5K
PRFZ
0.02% · 31.8K
BBC
0.83% · 23.1K
RSSL
0.03% · 20.5K
FHLC
0.01% · 18.3K
RFLR
0.12% · 6.2K
TILT
0.00% · 5.7K
ESSC
0.12% · 2.8K
BIB
0.04% · 2.2K
VETS
0.05% · 1.2K
USUE.DE
0.00% · 185
RESM
0.03% · 111

INSTITUTIONAL OWNERSHIP

SHARES OWNED
89.67%
HOLDERS
287
TOP 12 OF 287 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
11.2M sh · $171.87M
Fmr LLC
9.1M sh · $221.33M
Blackrock, Inc.
6.1M sh · $94.23M
Janus Henderson Group Plc
5.4M sh · $73.85M
State Street Corp
3.9M sh · $53.18M
Prosight Management, LP
3.8M sh · $58.44M
Paradigm Biocapital Advisors LP
2.9M sh · $71.37M
Vanguard Group Inc
2.9M sh · $40.11M
Adage Capital Partners Gp, L.L.C.
2.8M sh · $67.82M
Federated Hermes, Inc.
2.4M sh · $36.14M
Blackrock Inc.
2.3M sh · $98.19M
Point72 Asset Management, L.P.
2.0M sh · $30.63M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Campbell David Alan
Sale · 123.8K shares
2026-07-31
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Campbell David Alan
Sale · 7.0K shares
2026-07-08
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Campbell David Alan
Purchase · 7.0K shares
2026-07-08
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 15.5K shares
2026-06-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
OVERWEIGHT 2
UNDERWEIGHT 1
NEUTRAL 1
HOLD 1
12 GRADES IN THE LAST 12 MONTHS
Wolfe Research OUTPERFORM Guggenheim BUY Wedbush OUTPERFORM Piper Sandler OVERWEIGHT Jones Trading BUY Barclays UNDERWEIGHT UBS NEUTRAL Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
IMNM$27.57COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
HRMY$39.21COMPARE
ZYME$28.27COMPARE